Imugene Ltd (IMU)
Australian Securities Exchange · Australia · prices in AUD · close of 21 Oct 2026
Key indicators
| Last close | AUD 0.037 |
|---|---|
| 52-week range | 0.032 – 0.430 |
| Return, 1 month / 3 months | −21.3% / −58.9% |
| Return, 1 year / 3 years | −91.1% / −97.4% |
| Trend | Below its 200-day average |
| RSI (14) | 36 |
| Volatility (1 year) | 90.0% |
| Worst drawdown (1 year) | -91.6% |
| Average daily value traded | 0.15M AUD |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Imugene is an Australian clinical-stage immuno-oncology company based in Sydney. It develops cancer immunotherapies and oncolytic virus treatments designed to stimulate the body's immune system to attack tumours. Its pipeline includes modified oncolytic virus candidates and cancer vaccines aimed at a range of solid tumours. The company works with clinical investigators and research partners to test these therapies in patients, and its work is directed at oncology treatment rather than at consumer or industrial markets.
Imugene Ltd trades under the code IMU on the Australian Securities Exchange in Australia, with its price quoted in Australian dollars (AUD). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Imugene Ltd (IMU) trades on the Australian Securities Exchange in Australia. It last closed at AUD 0.037 on 21 October 2026.
Its price-based Market X-Ray is 17 out of 100 (a weak price profile), ranking 1,698 of 1,815 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 91.1% and over the last three months it fell 58.9%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Australian Securities Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 1 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -72.5% | ||
| From 52-week high | -90.9% | ||
| Momentum | 1 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -58.9% | ||
| 6-month return | -71.5% | ||
| 12-month return, skipping the last month | -88.7% | ||
| Stability (higher is calmer) | 18 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 90.0% | ||
| Worst drawdown, 1 year (smaller is calmer) | -91.6% | ||
| Liquidity | 65 · Fair | Moderate trading activity. | |
| Average daily value traded | 0.15M AUD | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
- Stability (higher is calmer): Volatile, with deep drawdowns.
Returns
| 1 week | +2.8% |
|---|---|
| 1 month | −21.3% |
| 3 months | −58.9% |
| 6 months | −71.5% |
| 1 year | −91.1% |
| 3 years | −97.4% |
| 5 years | −99.8% |
Signals
| 50-day / 200-day average | 0.055 / 0.135 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | Yes |
| Average daily range (ATR) | 0.004 |
Technical summary
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Australian Securities Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.